Loading company…
Restore Vision develops regenerative medicine and gene therapy for retinal and other eye diseases.
Founded in 2016 and based in Tokyo, Restore Vision develops regenerative medicine, including gene therapy for retinitis pigmentosa and optical sensor proteins for intractable eye diseases. Its chimeric rhodopsin genes are designed to function with sensitivity in patients. In April 2026, the company raised JPY 1.3 billion in pre-Series B funding from Astellas Venture Management, Ajinomoto Group Ventures, SHIONOGI, Japan Venture Capital Association, Higin Capital, Kyoto University Innovation Capital, JIC Venture Growth Investments, Japan Science and Technology Agency, and Remiges Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in